intravenous iv News
-
Amivas (US), LLC Announces FDA Approval of Artesunate for Injection for Treatment of Severe Malaria
Artesunate for Injection 110 mg, powder and solvent for solution is approved by FDA for initial treatment of severe malaria in adult and pediatric patients. Artesunate for Injection is in a group of drugs known as “artemisinin derivatives” and is on the World Health Organization Model List of Essential Medicines. Since 2007, Investigational Intravenous (IV) Artesunate has been ...
-
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of procurement options under its 75A50118C00019 (19C) contract with the U.S. Department of Health and Human Services for the delivery to the U.S. government of intravenous (IV) formulation of TPOXX treatment courses valued at ...
-
Grifols PharmacyKeeper ranked No. 1 in KLAS rating, extends category leadership
Fourth straight year in which the prestigious healthcare research firm selects PharmacyKeeper Verification as the No. 1 Category Leader for Intravenous (IV) Workflow Management PharmacyKeeper Verification is a strategic part of Grifols’ inclusiv portfolio, offering integrated technology, software and service solutions dedicated to advancing quality and safety in pharmacy operations ...
-
Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SeValent
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 17/546,880 filed on December 9, 2021 and titled Complexing Agent Salt Formulations of Pharmaceutical Compounds. Bexson’s ...
-
AmeriCares and Baxter work together to save lives in Haiti with donation to help Stem Cholera outbreak
AmeriCares and Baxter International Inc. have teamed to deliver additional lifesaving intravenous (IV) solutions to Haiti as part of their ongoing effort to stem the cholera outbreak. AmeriCares has been working around the clock to distribute IV solutions, oral rehydration salts, antibiotics, hand sanitizers and other critical aid since the outbreak was reported in October. As a leading ...
-
OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company. VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention ...
-
Christie Medical Holdings, Inc., & B. Braun Medical Announce Collaboration Aimed at Improving Peripheral IV Access Success
Christie® Medical Holdings, Inc., with its market-leading vein finder technology, VeinViewer® system, today announced an alliance with B. Braun Medical Inc., a leader in infusion therapy and pain management. Intravenous (IV) therapy plays a central role in patient care with as many as 90 percent of hospital patients receiving a peripheral IV catheter as part of their treatment plan. Many ...
-
BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19
BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for BCDA-04, a proprietary allogeneic mesenchymal cell (MSC) population that is Neurokinin-1 receptor positive ...
-
Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy
Ascelia Pharma AB (publ) (ticker: ACE) today announced the clinical development plan for Oncoral. With Oncoral, Ascelia Pharma has the opportunity to develop a novel oral chemotherapy with the potential to offer both efficacy and safety benefits to cancer patients. The planned Phase 2 study, for the treatment of gastric cancer, is expected to start in H2 2021. Further details of the Oncoral ...
-
PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn vector, NG-350A, to Re-Engineer Advanced Cancers
Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti- CD40 agonist. IV dosing of NG-350A led to elevations in IL-12, IFNγ and IL-17 that were higher and sustained for longer than those reported for systemic CD40 agonists. ...
-
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with SNK01 autologous natural ...
By Affimed GmbH
-
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval Positive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise interval TSC was safe and well-tolerated by all subjects with no serious adverse events reported Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) ...
By CervoMed
-
Dexamethasone reportedly part of President Trump’s Treatment
As part of the standard of care treatment protocol, President Trump received dexamethasone for his COVID-19 disease, highlighting the value of dexamethasone. Dexamethasone has been widely used since its initial approval in 1958 in treating acute disease. The use of higher dexamethasone doses, with potentially additional and desired immunological effects, is limited due the presence of toxic ...
-
ASC Therapeutics, UMass Chan Medical School, and the Clinic for Special Children Announce Podium Presentation of Safety and Efficacy in Murine and Bovine Models for Novel Gene Therapy in Maple Syrup Urine Disease
First known bovine model used to demonstrate safety and efficacy in gene replacement therapy MSUD is a severe genetic disease with liver transplantation or dietary restriction as the only treatments currently available ASC Therapeutics in partnership with the UMass Chan Medical School and the Clinic for Special Children (CSC), presented safety and efficacy results of a dual-function gene ...
-
Powering the Fight Against Malaria & Aids
Integrated Medical Industries Limited (IMIL), a Nigerian medical equipment maker, has contracted with Clarke Energy to install a captive power plant on the front line of the battle against malaria and aids. Double first: The manufacturing plant is the first World Health Organization (WHO) Performance Quality Safety (PQS) pre-qualified plant in Western Sub-Saharan Africa. This plant will ...
-
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Phase 1b/2 IMMCO-1 study of tivozanib and atezolizumab in multiple immunologically cold tumors AVEO Oncology (Nasdaq: AVEO), a commercial stage, ...
-
Imperative Care Announces U.S. Clearance of the ZOOM Aspiration System
Imperative Care, Inc., a company singularly dedicated to answering unsolved problems in stroke, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ZOOM™ Aspiration System – a family of products designed to facilitate clot removal during ischemic stroke. The ZOOM Aspiration System includes the ZOOM Reperfusion Catheters, ZOOM Aspiration ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you